日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語(yǔ)Fran?ais
China
Home / China / Latest

WHO resumes hydroxycholorquine trial after 'threat' queried

By CHEN WEIHUA in Brussels | chinadaily.com.cn | Updated: 2020-06-04 08:40
Share
Share - WeChat
WHO Director-General Tedros Adhanom Ghebreyesus. [Photo/Agencies]

The World Health Organization, or WHO, said on Wednesday that it will resume trials of anti-malaria drug hydroxycholorquine as a potential treatment of COVID-19 after having previously announced a temporary pause early last week.

WHO Director-General Tedros Adhanom Ghebreyesus said the executive group of the Solidarity Trial program had decided to implement a temporary pause last week because of concerns raised about the safety of the drug. The decision was taken as a precaution while the safety data was reviewed, something that has since been done by the Trial's Data Safety and Monitoring Committee.

"On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol," Tedros told a virtual news conference from Geneva.

"The executive group received this recommendation and endorsed continuation of all arms of the Solidarity Trial, including hydroxychloroquine."

He said the executive group will communicate with the principal investigators in the trial about resuming the hydroxychloroquine arm of the trial.

The WHO's announcement of a temporary halt, made on May 25, came after a paper published in medical journal The Lancet showed that people taking hydroxychloroquine were at higher risk of death and heart problems than those who were not.

The drug has been in the spotlight after United States President Donald Trump publicly promoted it at various occasions. Weeks ago, Trump claimed he was taking it as a precaution, but he said last week that he had finished taking it.

The Lancet articles have now turned out to be problematic. A report on ScienceMag.org on Tuesday said that the Lancet results have begun to unravel, and Surgisphere, which provided patient data for two other high-profile COVID-19 papers, has come under withering online scrutiny from researchers and amateur investigators.

They have pointed out many red flags in the Lancet paper, including the number of patients involved and details about their demographics and prescribed dosing that seem implausible.

"It began to stretch and stretch and stretch credulity," Nicholas White, a malaria researcher at Mahidol University in Bangkok, was quoted as saying.

On Wednesday, Soumya Swaminathan, the WHO's chief scientist, said she hopes the ongoing trial will continue until it has definite answers whether it works or not.

"That can only be done through well conducted randomized trials," she said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 亚洲欧美日韩精品久久奇米色影视 | 天天爽天天色 | 色开心婷婷 | 超级碰在线视频 | 99久久精品国产一区二区成人 | 99欧美精品 | 欧美激情在线观看一区二区三区 | 日本久久影视 | 一区二区在线不卡 | 亚洲欧美另类在线观看 | 国产精品v欧美精品v日韩精品 | 亚洲精品一区二区三区在线观看 | 欧美日韩精品乱国产 | 性视频一区二区 | 亚洲精品国产成人无码区A片 | 亚洲免费在线 | 欧美精品在线视频观看 | 黄色日本视频 | 免费看淫片 | 国产福利不卡视频在免费播放 | 天天看天天摸色天天综合网 | 成人伊人 | 久久激情综合色丁香 | 午夜精品毛片 | 国产精品日韩在线观看 | 老司机福利在线视频 | www.aiqingdao| 欧美黑人xxxx猛牲大交 | 精品久久网 | 欧美日韩福利视频 | 日本一区二区三区四区在线观看 | 激情网站 | 亚洲 欧美 日韩在线 | 久久久999精品视频 日本高清不卡在线 | 五月婷婷狠狠干 | 日本又黄又粗暴的gif动态图含羞 | 亚洲高清成人欧美动作片 | 久久成人18免费网站 | 欧美日日操| 日韩精品一级毛片 | 做羞羞视频 |